Ds-5141b    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy2

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 567 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04433234
(ClinicalTrials.gov)
July 8, 202012/6/2020Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyA Phase II, Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: DS-5141bDaiichi Sankyo Co., Ltd.NULLEnrolling by invitation5 YearsN/AMale8Phase 2Japan
2NCT02667483
(ClinicalTrials.gov)
October 201526/1/2016Study of DS-5141b in Patients With Duchenne Muscular DystrophyPhase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: DS-5141bDaiichi Sankyo Co., Ltd.Orphan Disease Treatment Institute Co., Ltd.Active, not recruiting5 Years10 YearsMale7Phase 1;Phase 2Japan